Ocular Therapeutix, Inc.
Clinical trials sponsored by Ocular Therapeutix, Inc., explained in plain language.
-
New eye implant shows promise for Long-Term wet AMD control
Disease control Recruiting nowThis study is checking the long-term safety of an implant called OTX-TKI (axitinib) for people with wet age-related macular degeneration (AMD). The implant is placed in the eye and slowly releases medicine to control the disease. About 850 people who already completed two years o…
Phase: PHASE3 • Sponsor: Ocular Therapeutix, Inc. • Aim: Disease control
Last updated Jul 02, 2026 06:00 UTC
-
New eye implant could slow vision loss in diabetes
Disease control Recruiting nowThis Phase 3 trial tests an implant called OTX-TKI that slowly releases the drug axitinib inside the eye. It aims to stop or slow worsening of non-proliferative diabetic retinopathy, a common diabetes complication that can lead to vision loss. About 930 adults with moderate to se…
Phase: PHASE3 • Sponsor: Ocular Therapeutix, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC